About
TCR Cell Therapy
Areas of Focus
Categories
Stem Cell & Cellular TherapyBoston & New England
Clinical Trials (3)
View allTotal Trials
3
As Lead Sponsor
1
As Collaborator
2
Total Enrollment
112
By Phase
PHASE1/PHASE2: 2PHASE1: 1
By Status
ACTIVE_NOT_RECRUITING: 2TERMINATED: 1
Clinical Trials Pipeline3 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Today
Hover over trial bars to see details
Recent Trials
NCT06105021Lead Sponsor
Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor
PHASE1/PHASE2Active, not recruiting
100 participants
Started: Mar 6, 2024 · Completed: Dec 31, 2029
NCT06043713Collaborator
Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Solid Tumor Cancers With KRAS G12V Mutations
PHASE1Active, not recruiting
5 participants
Started: Dec 15, 2023 · Completed: Feb 9, 2026
NCT03747484Collaborator
Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer
PHASE1/PHASE2Terminated
7 participants
Started: Jul 3, 2019 · Completed: Jan 9, 2024
Funding History (1)
D
Oct 15, 2024
Locations (1)
Headquarters
Watertown, MA, United States
Map
Loading map...